vs
Side-by-side financial comparison of ESAB Corp (ESAB) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
ESAB Corp is the larger business by last-quarter revenue ($727.8M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 7.5%, a 26.9% gap on every dollar of revenue. On growth, ESAB Corp posted the faster year-over-year revenue change (8.5% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 2.8%).
ESAB, Elektriska Svetsnings-Aktiebolaget, is an American-Swedish industrial company.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
ESAB vs RPRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $727.8M | $622.0M |
| Net Profit | $54.8M | $214.2M |
| Gross Margin | 37.0% | — |
| Operating Margin | 14.6% | 62.4% |
| Net Margin | 7.5% | 34.4% |
| Revenue YoY | 8.5% | 4.8% |
| Net Profit YoY | 2.1% | 2.9% |
| EPS (diluted) | $0.90 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $727.8M | $622.0M | ||
| Q3 25 | $715.6M | $609.3M | ||
| Q2 25 | $678.1M | $578.7M | ||
| Q1 25 | — | $568.2M | ||
| Q4 24 | $670.8M | $593.6M | ||
| Q3 24 | $673.3M | $564.7M | ||
| Q2 24 | $707.1M | $537.3M | ||
| Q1 24 | $689.7M | $568.0M |
| Q4 25 | $54.8M | $214.2M | ||
| Q3 25 | $66.9M | $288.2M | ||
| Q2 25 | $67.4M | $30.2M | ||
| Q1 25 | — | $238.3M | ||
| Q4 24 | $53.7M | $208.2M | ||
| Q3 24 | $68.2M | $544.0M | ||
| Q2 24 | $82.9M | $102.0M | ||
| Q1 24 | $60.0M | $4.8M |
| Q4 25 | 37.0% | — | ||
| Q3 25 | 37.2% | — | ||
| Q2 25 | 37.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 38.5% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 38.2% | — | ||
| Q1 24 | 37.0% | — |
| Q4 25 | 14.6% | 62.4% | ||
| Q3 25 | 15.2% | 70.1% | ||
| Q2 25 | 16.2% | 36.3% | ||
| Q1 25 | — | 94.0% | ||
| Q4 24 | 16.6% | 60.9% | ||
| Q3 24 | 15.7% | — | ||
| Q2 24 | 16.9% | 50.2% | ||
| Q1 24 | 16.0% | -13.0% |
| Q4 25 | 7.5% | 34.4% | ||
| Q3 25 | 9.3% | 47.3% | ||
| Q2 25 | 9.9% | 5.2% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | 8.0% | 35.1% | ||
| Q3 24 | 10.1% | 96.3% | ||
| Q2 24 | 11.7% | 19.0% | ||
| Q1 24 | 8.7% | 0.8% |
| Q4 25 | $0.90 | $0.49 | ||
| Q3 25 | $1.09 | $0.67 | ||
| Q2 25 | $1.10 | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | $0.87 | $0.46 | ||
| Q3 24 | $1.11 | $1.21 | ||
| Q2 24 | $1.35 | $0.23 | ||
| Q1 24 | $0.98 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.2M | $618.7M |
| Total DebtLower is stronger | $1.3B | $9.0B |
| Stockholders' EquityBook value | $2.1B | $9.7B |
| Total Assets | $4.9B | $19.6B |
| Debt / EquityLower = less leverage | 0.63× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.2M | $618.7M | ||
| Q3 25 | $258.2M | $938.9M | ||
| Q2 25 | $291.3M | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $249.4M | $929.0M | ||
| Q3 24 | $253.7M | $950.1M | ||
| Q2 24 | $228.5M | $1.8B | ||
| Q1 24 | $76.5M | $843.0M |
| Q4 25 | $1.3B | $9.0B | ||
| Q3 25 | $1.1B | $8.9B | ||
| Q2 25 | $1.1B | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.1B | $7.6B | ||
| Q3 24 | $1.1B | $7.6B | ||
| Q2 24 | $1.1B | $7.6B | ||
| Q1 24 | $992.8M | $6.1B |
| Q4 25 | $2.1B | $9.7B | ||
| Q3 25 | $2.1B | $9.6B | ||
| Q2 25 | $1.9B | $9.5B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | $1.8B | $10.3B | ||
| Q3 24 | $1.8B | $10.3B | ||
| Q2 24 | $1.7B | $9.8B | ||
| Q1 24 | $1.6B | $9.9B |
| Q4 25 | $4.9B | $19.6B | ||
| Q3 25 | $4.4B | $19.3B | ||
| Q2 25 | $4.2B | $18.3B | ||
| Q1 25 | — | $17.6B | ||
| Q4 24 | $4.0B | $18.2B | ||
| Q3 24 | $4.1B | $18.0B | ||
| Q2 24 | $4.0B | $17.7B | ||
| Q1 24 | $3.8B | $16.1B |
| Q4 25 | 0.63× | 0.92× | ||
| Q3 25 | 0.51× | 0.93× | ||
| Q2 25 | 0.55× | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.60× | 0.74× | ||
| Q3 24 | 0.59× | 0.74× | ||
| Q2 24 | 0.63× | 0.78× | ||
| Q1 24 | 0.61× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $81.5M | $827.1M |
| Free Cash FlowOCF − Capex | $70.3M | — |
| FCF MarginFCF / Revenue | 9.7% | — |
| Capex IntensityCapex / Revenue | 1.5% | — |
| Cash ConversionOCF / Net Profit | 1.49× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $238.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $81.5M | $827.1M | ||
| Q3 25 | $46.6M | $702.6M | ||
| Q2 25 | $35.4M | $364.0M | ||
| Q1 25 | — | $596.1M | ||
| Q4 24 | $126.9M | $742.5M | ||
| Q3 24 | $101.0M | $703.6M | ||
| Q2 24 | $83.0M | $658.2M | ||
| Q1 24 | $44.5M | $664.6M |
| Q4 25 | $70.3M | — | ||
| Q3 25 | $37.4M | — | ||
| Q2 25 | $28.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $102.2M | — | ||
| Q3 24 | $90.4M | — | ||
| Q2 24 | $74.0M | — | ||
| Q1 24 | $37.1M | — |
| Q4 25 | 9.7% | — | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 15.2% | — | ||
| Q3 24 | 13.4% | — | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.4% | — |
| Q4 25 | 1.5% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 1.49× | 3.86× | ||
| Q3 25 | 0.70× | 2.44× | ||
| Q2 25 | 0.53× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | 2.36× | 3.57× | ||
| Q3 24 | 1.48× | 1.29× | ||
| Q2 24 | 1.00× | 6.45× | ||
| Q1 24 | 0.74× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESAB
| Consumable Products | $477.9M | 66% |
| Equipment Products | $249.9M | 34% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
